FDA says Teva addressed issues at Jerusalem plant
TEL AVIV, Sept 13
TEL AVIV, Sept 13 (Reuters) - Teva Pharmaceutical Industries said it received a close-out letter from the U.S. Food and Drug Administration notifying the company that it has addressed issues raised following an inspection of its Jerusalem plant.
The issues had been raised by the FDA in a warning letter received on Jan. 31 connected with an FDA "Good Manufacturing Practices" inspection of the oral solid dosage plant in Jerusalem.
"The FDA completed a reinspection of the company's Jerusalem facility on June 19, 2011, which resulted in no adverse findings," Israel-based Teva said on Tuesday.
Chief Financial Officer Eyal Desheh said in July the Jerusalem plant would return to normal production in the third quarter.
(Reporting by Tova Cohen; Editing by Hans-Juergen Peters)
- Police seek motive in fatal Washington state school shooting
- Two deputies killed, two others hurt in California shooting spree
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Wall St. finally turning on Amazon as Bezos magic fades
- U.S., allies stage 22 air strikes in Iraq: U.S. Central Command